Copenhagen - Free Realtime Quote DKK

Zealand Pharma A/S (ZEAL.CO)

236.80 +2.60 (+1.11%)

As of 2:56:11 PM GMT+1. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830

GlobeNewswire 16d ago

ZEAL.CO
+1.11%
Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes

GlobeNewswire 27d ago

ZEAL.CO
+1.11%
Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)

GlobeNewswire 29d ago

ZEAL.CO
+1.11%
DANSKE.CO
Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes

GlobeNewswire 1mo ago

ZEAL.CO
+1.11%
Total number of shares and voting rights in Zealand Pharma as of September 30, 2026

GlobeNewswire 1mo ago

ZEAL.CO
+1.11%
Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology

GlobeNewswire 1mo ago

ZEAL.CO
+1.11%
Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)

GlobeNewswire 1mo ago

ZEAL.CO
+1.11%
Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity

GlobeNewswire 1mo ago

ZEAL.CO
+1.11%
Zealand Pharma - Transactions related to share buy-back program (week 38, 2026)

GlobeNewswire 1mo ago

ZEAL.CO
+1.11%
Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome

GlobeNewswire 1mo ago

ZEAL.CO
+1.11%
Zealand Pharma - Transactions related to share buy-back program (week 37, 2026)

GlobeNewswire 1mo ago

ZEAL.CO
+1.11%
Zealand Pharma increases its share capital as a result of the exercise of employee warrants

GlobeNewswire 1mo ago

ZEAL.CO
+1.11%

Performance Overview

Return	ZEAL.CO	OMX Copenhagen 25 Index (^OMXC25)
YTD	-49.23%	+11.77%
1-Year	-52.70%	+20.89%
3-Year	-22.36%	+24.71%

U.S. markets open in 34m

Zealand Pharma A/S (ZEAL.CO)

Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830

Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes

Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)

Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes

Total number of shares and voting rights in Zealand Pharma as of September 30, 2026

Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology

Zealand Pharma - Transactions related to share buy-back program (week 39, 2026)

Zealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesity

Zealand Pharma - Transactions related to share buy-back program (week 38, 2026)

Zealand Pharma receives positive CHMP opinion for Zeydovio™ (glepaglutide) for the treatment of short bowel syndrome

Zealand Pharma - Transactions related to share buy-back program (week 37, 2026)

Zealand Pharma increases its share capital as a result of the exercise of employee warrants